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Abstract
Background: Diabetes predisposes to sudden cardiac death (SCD). However, it is uncertain whether greater
proportion of cardiac deaths are sudden among diabetes patients than other subjects. It is also unclear whether the
risk of SCD is pronounced already early in the course of the disease. The relationship of impaired glucose tolerance
(IGT) and SCD is scarcely documented.
Methods: A general population cohort of 10594 middle-aged subjects (mean age 44 years, 52.6 % male, follow-up
duration 35–41 years) was divided into diabetes patients (n = 82), subjects with IGT (n = 3806, plasma glucose
≥9.58 mmol/l in one-hour glucose tolerance test), and controls (n = 6706).
Results: Diabetes patients had an increased risk of SCD after adjustment confounders (hazard ratio 2.62, 95 %
confidence interval 1.46–4.70, p = 0.001) but risk for non-sudden cardiac death was similarly increased and the
proportion of SCD of cardiac deaths was not increased. The SCD risk persisted after exclusion of subjects with
baseline cardiac disease or non-fatal cardiac events during the follow-up. Subjects with IGT were at increased risk
for SCD (univariate hazard ratio 1.51; 95 % confidence interval 1.31–1.74; p < 0.001) and also for non-sudden cardiac
deaths and non-fatal cardiac events but adjustments for other risk factors attenuated these effects.
Conclusions: Diabetes was associated with increased risk of SCD but also the risk of non-sudden cardiac death was
similarly increased. The proportion of cardiac deaths being sudden in subjects with diabetes was not increased. The
higher SCD risk in diabetes patients was independent of known cardiac disease at baseline or occurrence of non-
fatal cardiac event during the follow-up.
Keywords: Death, sudden, cardiac, Diabetes mellitus, Diabetic cardiomyopathies, Prediabetic state, Prospective
studies
Background
Sudden cardiac death (SCD) is estimated to account for
50 % of deaths from cardiovascular causes and about
half of these deaths occur in subjects who are not previ-
ously diagnosed with heart disease [1, 2]. Coronary
artery disease is the underlying cause in 80 % of SCDs,
consequently, risk factors for coronary artery disease
also predispose to SCD [1]. Diabetes is a well-established
risk factor for coronary artery disease [3]. Diabetes also
predisposes patients to heart failure – an important risk
factor for SCD – independent of other risk factors of
heart failure [2–4]. In addition to coronary artery disease
and heart failure, cardiac autonomic neuropathy (CAN),
a late complication of diabetes, might explain the
increased incidence of SCD among diabetes patients. In-
creased prevalence of silent myocardial ischemia and
QT interval prolongation have been documented among
diabetes patients with CAN and this at least partly ex-
plains the observed three-fold increase in mortality and
higher proportion of deaths attributed to SCD among sub-
jects with CAN [5]. Interestingly, changes in measures of
autonomic function have also been documented in sub-
jects with glucose levels in the prediabetic range [6].
Expectedly, diabetes has been shown to be associated
with approximately two-fold risk of SCD [7]. However,
epidemiologic evidence suggests that diabetes might not
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be specifically associated with the risk of SCD as it is
generally thought that also the risk of non-sudden car-
diac death increases similarly among diabetes patients
although opposite evidence exists as well [8, 9]. The tim-
ing of the SCD risk in the course of diabetes has not
been comprehensively studied but it warrants attention
as coronary artery disease generally develops early in the
course of diabetes but heart failure and CAN are late
complications [3]. Also prediabetic dysglycemic states,
such as impaired fasting glucose (IFG) and impaired
glucose tolerance (IGT) are associated with increased
cardiovascular mortality but little is known of the associ-
ation of IGT and SCD [10]. In this work we studied the
risks of sudden and non-sudden cardiac deaths associ-
ated with IGT and diabetes in subjects with and without
heart disease. We also tested whether QT interval
lengthening and acceleration of heart rate, electrocardio-
graphic markers of CAN, would separate diabetes pa-
tients dying suddenly from cardiac causes.
Material and methods
Study population
The study population consists of 10957 men and women
aged 30–59 years who took part in the Coronary Heart
Disease Study of the Finnish Mobile Clinic (FMC)
Health Examination Survey between 1966 and 1972. The
survey was carried out in 12 localities in Finland and the
sample represented well the Finnish middle-aged popu-
lation. The overall participation rate was 89.6 % (total
12310 invited subjects). The study rationale and proce-
dures performed at the baseline examinations have been
described previously [11]. At baseline a standard 12-lead
electrocardiogram (ECG) was recorded and blood pres-
sure, body mass index (BMI), and serum cholesterol were
measured. The subjects also completed a questionnaire re-
garding their health habits, known diseases, medication,
smoking habits, and symptoms of cardiovascular disease.
Subjects who had not been diagnosed with diabetes had
an oral glucose tolerance test (OGTT) but for practical
reasons a venous blood sample was drawn only once at
1 h after the glucose load. The sample was centrifuged
immediately and separated plasma samples were frozen
for analyses 1–3 weeks later. Plasma glucose concentra-
tion was measured by an autoanalyzer modification
(Technicon Auto-Analyzer Methodology N2- b) of the
ferricyanide reduction method. The glucose load as a 20 %
solution was intended to be 40 g/m2 body surface area but
for practical reasons fixed doses of 60, 75, or 90 g were
used the 75 g dose being the most frequently administered
[11]. The type of diabetes was not specifically documented
during the data collection but it is likely that a major part
of the subjects using insulin had type 1 diabetes and sub-
jects treated with tablet medication or diet had type 2 dia-
betes. The ECGs were interpreted by nine trained readers
and coded according to the revised Minnesota code (MC)
[11, 12]. We excluded subjects with missing or unreadable
ECGs (n = 53), subjects in whom the OGTT was not per-
formed for reasons other than known diabetes (n = 121),
subjects in whom the assessment of QT interval corrected
for heart rate according to Bazett’s formula (QTc) was un-
reliable (n = 51, 16 of these due to atrial fibrillation), sub-
jects with missing blood pressure (n = 128), subjects with
2nd or 3rd degree atrioventricular block (n = 1), or Wolff-
Parkinson-White-pattern (n = 4) and also rest of the sub-
jects with atrial fibrillation or flutter (n = 5), and thus we
were left with 10594 subjects for data-analysis. The FMC
survey precedes current legislation on ethics in medical
research. All participants were fully informed about the
study, they participated in the study voluntarily and the use
of the information for medical research was explained to
them. Agreeing to participate in the baseline health exam-
ination was taken to indicate informed consent. The
follow-up study using record linkage to the Care Register
for Health Care (THL/924/6.02.00/2011) was approved by
the Ethical Committee of the National Institute for Health
and Welfare on June 8, 2011. Statistics Finland approved
linkage to Causes of Death Register (TK-53–588–12).
These registries decide on providing data for research pur-
poses based on an application procedure.
Follow-Up
From the baseline examination the subjects were
followed for 35–41 years until the end of 2007. Less
than 2 % of the subjects were lost to follow-up, but also
for the majority of this group the survival status could
still be determined. The mortality data were obtained
from the Causes of Death Register maintained by Sta-
tistics Finland. The death certificates were obtained for
each deceased. All deaths from cardiac causes were
reviewed by two experienced cardiologists (O.A. and
H.V.H.) by the use of hospital records and necropsy re-
ports, if available, to identify sudden deaths from
arrhythmia based on the definitions presented in the
Cardiac Arrest Pilot Study [13], as described by our
group previously [14]. Briefly, SCD was defined as a
spontaneous cessation of respiration and circulation
with loss of consciousness either instantaneously or
preceded by symptoms attributable to arrhythmia or
myocardial ischemia in the absence of heart failure.
Also unwitnessed deaths without evidence of another
cause were classified as SCD. In addition, episodes of
coronary heart disease and congestive heart failure re-
quiring hospitalization were obtained from the Care
Register for Health Care (HILMO) maintained by The
National Institute for Health and Welfare which re-
cords nationwide data on all inpatient episodes in
Finland. The accuracy of these registers has proven to
be good [15].
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Statistical analyses
Due to the lack of a standard cutoff point for plasma
glucose concentration in 1-h OGTT in diagnosing IGT
we used a Receiver operating characteristics (ROC) ana-
lysis to determine the 1-h glucose value providing max-
imal sensitivity plus specificity in discriminating subjects
whose cause of death was classified as SCD from other
subjects and used this value as the cutoff for IGT. The
differences in characteristics of subjects with normal
glucose tolerance, IGT and diabetes were compared
using ANOVA for continuous variables and Chi-Square
test for categorical variables. The Chi-Square test was
used to compare proportions of cardiac deaths and non-
cardiac deaths and SCD and non-sudden cardiac deaths.
Our primary outcome was SCD, but analyses were also
made with non-sudden cardiac death, and a composite
of hospitalization for coronary heart disease and con-
gestive heart failure as the end-point. The hazard ratios
(HRs) and their 95 % confidence intervals (95 % CIs)
were calculated using the Cox proportional hazards
model. The covariates were selected based on previous
evidence of an association with cardiovascular mortality.
Age, BMI, systolic blood pressure, cholesterol, QTc, and
heart rate were used as continuous variables and sex,
smoking status, cardiac disease in the baseline, electro-
cardiographic signs of myocardial infarction, and elec-
trocardiographic signs of coronary artery disease were
used as binary variables. A subject was defined as having
cardiac disease in the baseline if a “yes” answer was
present in the baseline questionnaire in at least one of
the following questions: Do you have or have you had 1)
valvular disease, 2) congestive heart failure, 3) angina pec-
toris, 4) myocardial infarction, or 5) congenital heart
disease? Electrocardiographic signs of myocardial infarc-
tion were defined by the presence of definitely patho-
logical Q-waves (MC 1–1) or Q-waves in the presence of
T wave inversions (MC 1–2 and 5–1 or 5–2). Electrocar-
diographic signs of coronary artery disease were defined
as the presence of minor Q-waves (MC 1–2 or 1–3), ST-
segment depressions (MC 4–1, 4–2, or 4–3), T-wave in-
versions (MC 5–1 or 5–2), or ventricular conduction
defects (MC 7–1, 7–2, or 7–4). The follow-up time was
defined as the number of days from the baseline examin-
ation to the event of interest, death or the end of follow-
up, whichever came first. The general linear model was
used to assess the age- and sex adjusted means of QTc
and heart rate among diabetes patients with different
causes of death. All p values are two-sided. The statistics
analyses were made with the Statistical Package for Social
Studies, version 22 (SPSS).
Results
The ROC analysis for plasma glucose concentration in
1-h OGTT yielded maximum sensitivity plus specificity
in discriminating subjects whose cause of death was
classified as SCD at 9.58 mmol/l (172.5 mg/dl). Using
this value as the cutoff for IGT, 3806 subjects (35.9 %)
had IGT, 82 subjects (0.8 %) had diabetes, and 6706 sub-
jects (63.3 % of all subjects) had normal glucose
tolerance.
Baseline characteristics of subjects
The baseline characteristics of subjects are presented in
Table 1. Subjects with IGT and diabetes were generally
older, had higher cholesterol, body mass index, blood
pressure, heart rate and QTc, and they had more often
electrocardiographic signs of coronary artery disease
than subjects with normal glucose tolerance. When the
baseline characteristics of males and females were
compared in the groups of normal, IGT, and diabetes
patients, QTc and heart rate were lower in men in all
groups. Systolic and diastolic blood pressures were
higher among women with diabetes than men with dia-
betes. Smoking and left ventricular hypertrophy were
more prevalent in all groups of men than in women
(data not shown). The treatments used among diabetes
patients were insulin (n = 24), sulphonylureas (n = 23) or
biguanides (n = 8) or both (n = 9), and diet (n = 18).
Mortality and non-fatal cardiac events
During the follow-up 3503 (52.2 %) subjects with normal
glucose tolerance, 2363 (62.1 %) subjects with IGT and
80 (97.6 %) subjects with diabetes died. Mortality was
higher among men than among women (63.9 % vs
47.4 %, respectively). The proportions of cardiac and
non-cardiac deaths, and sudden and non-sudden cardiac
deaths are presented in Table 2. A high percentage of
cardiac deaths was observed among males with diabetes,
among whom 56.5 % of deaths were cardiac. For females
the proportion of cardiac deaths was the same in all
groups. The proportions of SCD and non-sudden cardiac
deaths were similar among subjects with IGT and dia-
betes compared to normal subjects. During the follow-
up 31.6 % of normal subjects, 34.7 % of subjects with
IGT and 52.4 % of diabetes patients were hospitalized
for coronary heart disease and 14.9 % of normal sub-
jects, 16.8 % of subjects with IGT and 41.5 % of diabetes
patients were hospitalized for congestive heart failure.
Roles of IGT and diabetes as risk factors for SCD
and other cardiac events
The roles of IGT and diabetes as risk factors for SCD,
non-sudden cardiac death and non-fatal cardiac events
were assessed in Cox proportional hazard models. The
results of these models are presented in Table 3. IGT
was associated with increased risk of SCD, non-sudden
cardiac death and non-fatal cardiac events only in the
univariate models. Diabetes was strongly associated with
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SCD and similarly with non-sudden cardiac deaths and
non-fatal cardiac events even after a comprehensive
multivariate adjustment. Adjustment for electrocardio-
graphic abnormalities had minor impact on the HRs.
These models were also conducted separately for males
and females giving similar results with the exception of
the risk of SCD among females with diabetes in which
the risk estimate was uncertain because only one female
with diabetes died of SCD.
Subgroup analyses
The Cox proportional hazards models with SCD and
non-sudden cardiac death as end-point were also con-
ducted among subjects who were not hospitalized due to
coronary heart disease or congestive heart failure during
the follow-up and who were free of cardiac disease at
baseline. There were 4031, 2088, and 24 subjects and
206, 146, and 4 SCDs in groups of normal, IGT and dia-
betes patients, respectively. In these models IGT and dia-
betes predicted SCD univariately (IGT HR 1.50, 95 % CI
1.22–1.86, p < 0.001 and diabetes HR 8.40, 95 % CI
3.11–22.65, p < 0.001). In the multivariate models (vari-
ables as in Table 2 excluding baseline cardiac disease)
only diabetes predicted SCD significantly, the hazard ra-
tios being 4.21 (95 % CI 1.55–11.40, p = 0.005) and 3.52
(95 % CI 1.28–9.67, p = 0.015) for models 1 and 2, respect-
ively. The results were virtually similar when non-sudden
cardiac death was the end-point in corresponding models.
To assess the risk of SCD, non-sudden cardiac death
and non-fatal cardiac events in patients with probable
type 2 diabetes (diabetes patients not treated with insu-
lin), the models presented in Table 3 were re-conducted
after exclusion of diabetes patients treated with insulin.
The results remained virtually the same in these models.
To lessen the impact of new diabetes cases presenting
during the follow-up, we also conducted separate models
in which the follow-up time was truncated to 10 years.
The multivariate-adjusted hazard ratios for SCD and
non-fatal cardiac events among diabetes patients were
similar to those in models with complete follow-up but
the multivariate adjusted hazard ratio for non-sudden
cardiac death was smaller and no statistical significance
was reached in these models. However, there were only
4 SCDs and 3 non-sudden cardiac deaths among dia-
betes patients during the first 10 years of follow-up
which led to wide confidence intervals.
Table 1 Baseline characteristics of subjects
Normal (n = 6706) IGT (n = 3806) Diabetes (n = 82) P
Male, % 53.3 51.4 57.3 0.142
Age, years 42.9 (8.2, 42.7–43.1) 45.7 (8.5, 45.4–45.9) 50.1 (7.6, 48.5–51.8) <0.001
BMI, kg/m2 25.6 (3.6, 25.5–25.7) 26.3 (4.1, 26.2–26.5) 28.5 (5.3, 27.3–29.6) <0.001
Systolic blood pressure, mmHg 134.8 (19.8, 134.3–135.2) 144.6 (22.7, 143.8–145.3) 148.4 (25.6, 142.8–154.0) <0.001
Diastolic blood pressure, mmHg 80.6 (11.8, 80.4–80.9) 84.7 (13.0, 84.3–85.2) 87.9 (13.3, 84.9–90.8) <0.001
Cholesterol, mmol/l 6.4 (1.3, 6.4–6.5) 6.6 (1.4, 6.5–6.6) 6.9 (1.5, 6.6–7.2) <0.001
Smoker, % 36.0 30.6 30.5 <0.001
Cardiac disease, % 6.9 9.6 23.2 <0.001
Heart rate, bpm 73.6 (14.1, 73.2–73.9) 78.8 (16.5, 78.3–79.3) 79.3 (15.8, 75.8–82.7) <0.001
QRS duration, ms 86.9 (8.4, 86.7–87.1) 87.1 (8.6, 86.8–87.3) 88.5 (11.9, 85.9–91.1) 0.163
QTc, ms 404.6 (26.9, 403.9–405.2) 414.6 (27.5, 413.7–415.4) 415.4 (31.2, 408.5–422.2) <0.001
Left ventricular hypertrophya, % 30.5 33.2 25.6 0.008
Electrocardiographic signs of myocardial infarction, % 0.4 0.7 4.9 <0.001
Electrocardiographic signs of coronary artery disease, % 8.5 11.9 23.2 <0.001
aAssessed with Sokolow-Lyon electrocardiographic criterion
Table 2 Proportions of cardiac and non-cardiac deaths and sudden and non-sudden cardiac deaths by diabetes status
Causes of death Normal (n = 3504) IGT (n = 2364) Diabetes (80) p
Non-cardiac 2370 (67.6 %) 1558 (65.9 %) 45 (56.3 %) 0.050
Cardiac 1134 (32.4 %) 806 (34.1 %) 35 (43.8 %)
Suddenness of cardiac deaths Normal (n = 1134) IGT (n = 806) Diabetes (n = 35) p
Non-arrhythmic 697 (61.5 %) 470 (58.3 %) 23 (65.7 %) 0.302
Arrhythmic 437 (38.5 %) 336 (41.7 %) 12 (34.3 %)
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QTc, heart rate and causes of death among diabetes
patients
The general linear model was used to calculate age- and
sex-adjusted mean QTc and heart rate, markers of CAN,
among diabetes patients and compared the means
according to the cause of death. These results are pre-
sented in Table 4. The means for QTc were slightly lon-
ger and heart rate was slightly faster among diabetes
patients who had died of cardiac causes but no statistical
significance was reached in these analyses.
Discussion
In this study we assessed the risk of SCD and other car-
diac events associated with diabetes and IGT. Special
emphasis was on whether the risk of SCD would be pro-
nounced over the risk of non-sudden cardiac death
among diabetes patients and the timing of the SCD risk
associated with diabetes.
We expectedly observed that diabetes was associated
with increased risk of SCD and also with increased risk
of non-sudden cardiac death. However, diabetes was not
specifically related to the risk of SCD as the proportion
of SCD of all cardiac deaths did not increase, and the
hazard ratios for SCD and non-sudden cardiac death
were largely similar among diabetes patients. The sud-
denness of cardiac deaths among diabetes patients com-
pared to subjects without diabetes has been under
debate but generally diabetes is believed to have similar
influence on the risk of SCD and non-sudden cardiac
death [8]. This is supported by recent findings from the
large population-based Atherosclerosis Risk in Commu-
nities study in which both the incidence rate of SCD and
non-sudden cardiac death were 4-fold higher and
multivariate-adjusted hazard ratios for these end-points
were largely similar among diabetes patients. Also the
proportions of SCD of all cardiac deaths were virtually
the same between diabetes patients and healthy subjects
in this study [16]. Some evidence to the contrary also
exist as in the Paris Prospective Study diabetes was asso-
ciated with increased risk of SCD but not for increased
risk of non-fatal myocardial infarction [9].
Predictably, the diabetes patients were also at in-
creased risk of hospitalizations for coronary heart dis-
ease and congestive heart failure as these conditions are
frequent complications of diabetes [3]. Thus, a large por-
tion of diabetes patients had either or both coronary
Table 3 The HRs for sudden and non-sudden cardiac death and for non-fatal cardiac events
Sudden cardiac death Normal (n = 6706) IGT (n = 3806) P Diabetes (n = 82) P
No. of events 437 336 12
Unadjusted HR 1 (reference) 1.51 (1.31–1.74) <0.001 5.52 (3.10–9.82) <0.001
Model 1a 1 (reference) 1.16 (1.00–1.35) 0.045 2.62 (1.46–4.70) 0.001
Model 2b 1 (reference) 1.14 (0.98–1.32) 0.088 2.40 (1.34–4.33) 0.003
Non-sudden cardiac death Normal (n = 6706) IGT (n = 3806) p Diabetes (n = 82) p
No. of events 697 470 23
Unadjusted HR 1 (reference) 1.36 (1.21–1.53) <0.001 8.43 (5.50–12.81) <0.001
Model 1a 1 (reference) 0.94 (0.83–1.06) 0.321 3.05 (1.99–4.67) <0.001
Model 2b 1 (reference) 0.92 (0.82–1.04) 0.194 2.90 (1.89–4.46) <0.001
Non-fatal cardiac events Normal (n = 6706) IGT (n = 3806) p Diabetes (n = 82) p
No. of events 2483 1573 56
Unadjusted HR 1 (reference) 1.27 (1.19–1.35) <0.001 6.47 (4.95–8.44) <0.001
Model 1a 1 (reference) 0.99 (0.92–1.05) 0.693 3.63 (2.77–4.75) <0.001
Model 2b 1 (reference) 0.99 (0.92–1.05) 0.680 3.50 (2.67–4.59) <0.001
aModel 1: Adjusted for age, sex, BMI, systolic blood pressure, cholesterol, smoking, and baseline cardiac disease
bModel 2: Adjusted for age, sex, BMI, systolic blood pressure, cholesterol, smoking, baseline cardiac disease, heart rate, QTc, electrocardiographic signs of
myocardial infarction, and electrocardiographic signs of coronary artery disease
Table 4 Mean QTc and heart rate among diabetes patients with different causes of death
n Mean QTc, ms (SD, 95 % CI) pa Mean heart rate, bpm (SD, 95 % CI) pa
Alive or non-cardiac death 47 412 (31, 402–421) 78 (16, 73–82)
Non-sudden cardiac death 23 419 (32, 406–432) 0.360 81 (12, 75–87) 0.441
Sudden cardiac death 12 423 (33, 404–442) 0.290 81 (21, 72–90) 0.565
aThe p values test the difference of group mean compared to the mean of group alive/non-cardiac death
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heart disease and congestive heart failure, both import-
ant risk factors for SCD, which explains partly the in-
creased incidence of SCDs among the diabetes patients.
However, the diabetes patients were at increased risk of
SCD and non-sudden cardiac death also when subjects
with overt heart disease were excluded from the models
suggesting that diabetes increases the risk of these
events, independently of diagnosed cardiac disease. This
is a significant observation as it would sound reasonable
that the increment in SCD risk associated with diabetes
is largely mediated through the increased burden of
heart failure, severe diffuse coronary atherosclerosis and
CAN which are late complications of diabetes [3]. The
matter has received only little attention previously but
prior reports are in line with the findings of the present
study. In previous prospective studies, inclusion or ex-
clusion of subjects with pre-existing vascular disease did
not markedly alter the observed risk of SCD [7]. In a
large case–control study the point estimates of HR for
SCD associated with diabetes were larger in subjects
without heart disease but the models were adjusted for
slightly different sets of confounders [17]. In one cohort
study based on a female population the HR for SCD as-
sociated with diabetes was 2.0 in the whole population
and 2.2 when subjects with coronary heart disease were
excluded but subjects with heart failure were still in-
cluded in the model [18].
Thus, it seems that the risk of SCD, non-sudden car-
diac death, and non-fatal cardiac events increase simi-
larly in diabetes so the risk of SCD is not specifically
pronounced. Finding markers identifying subjects specif-
ically at high risk for SCD from those subjects with an
overall elevated risk of death from cardiac causes would
be beneficial for efforts to reduce SCD burden in the
population. Diabetes seems to lack this specificity as do
most of the currently available risk markers of SCD [2].
Diabetes also seems to be associated with increased risk
of SCD already before the development of overt heart
disease. However, in any future studies with larger num-
bers of subjects with diabetes these issues should be
assessed by stratifying for the type and duration of dia-
betes. In type 2 diabetes coronary atherosclerosis begins
to develop already in a prediabetic state in contrast to
the other possibly arrhythmogenic complications of dia-
betes such as heart failure, CAN, and cardiac fibrosis
that appear as later manifestations [3]. The presence of
microvascular disease is associated with an increased risk
of SCD in diabetes patients [17]. It has also been shown
that in myocardial infarction patients with diabetes a lar-
ger proportion of deaths are sudden compared to myocar-
dial infarction patients without diabetes [19, 20]. It is
reasonable to assume that the diabetes patients who
already have had a myocardial infarction or who have de-
veloped microvascular disease are in an advanced state of
diabetes compared to the ones in prospective population
based studies. This may explain the differences in findings
between population based studies and the studies men-
tioned above.
In our study IGT predicted SCD and other cardiac
events univariately but adjustment for confounders at-
tenuated this effect. IGT is a risk factor for diabetes and
part of the metabolic syndrome which is an established
risk factor for cardiovascular disease, but it is difficult to
assess the individual contribution of IGT as it often pre-
sents with other important risk factors such as hyperten-
sion, dyslipidemia, obesity, and proinflammatory and
prothrombotic states [21]. In a recent systematic review
with follow-up times of individual studies ranging from
5 to 21.5 years, the pooled relative risk of fatal and non-
fatal cardiac events associated with IGT was 1.20 (95 %
CI 1.07–1.34) but the degree of adjustment was limited
in many of the included studies [22]. These data, to-
gether with the results of the present study suggest that
no notable changes in the risk are associated with IGT
even in a longer follow-up. The relationship of IGT and
SCD risk has been less thoroughly investigated. In the
Paris Prospective Study I middle-aged males with IGT
were at increased risk for SCD based on analysis of cu-
mulative mortality curves [9]. In a 23-year follow-up of
men of Japanese ancestry living on the island of Oahu
on Hawaii the risk of SCD gradually increased with
worsening glucose tolerance in a 1-h OGTT despite
multivariate adjustment [23]. The relative risks of SCD
in that study were 1.59 and 2.22 in subjects with OGTT
results 8.39–12.44 and ≥12.45 mmol/l, respectively, com-
pared to subjects with normal glucose tolerance [23].
Interestingly, in recent study impaired fasting plasma glu-
cose was shown to be associated with a 1.5-fold risk of
SCD after a comprehensive multivariate adjustment in a
male population [24]. Thus, also prediabetic hypergly-
cemic states seem to predict SCDs in addition to other
cardiac events but the topic warrants further studies to de-
fine their final value in risk stratification.
We did not find significant differences in mean QTc
or heart rate in diabetes patients grouped according to
their cause of death. However, our sample of subjects with
diabetes was small to detect differences in such variables
with large between-subject variance. A high resting heart
rate is characteristic in patients with CAN and there is a
particularly strong association between CAN and QTc
lengthening [25, 26]. Previously, in one case–control study
consisting of diabetes patients free of cardiac disease at
baseline, the subjects in the fourth QT interval quartile
were at 3-fold increased risk for SCD compared with the
first quartile [27]. However, in that study the mean follow-
up time from the ECG to event among SCD victims was
5.1 years whereas in our study among diabetes patients it
was 12.8 years which may give an explanation as to why
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we did not observe differences in QTc and heart rate. It
may be that the subjects of the present study developed
CAN, QTc lengthening, and higher heart rate only during
the follow-up. Anyhow, given the previous encouraging
results of the use of QTc and heart rate in SCD risk strati-
fication among diabetes patients this issue should be stud-
ied in larger populations of diabetes patients in the future.
The strengths of our study include a large population
and a long and comprehensive follow up. The main
weakness of our study was that the amount of subjects
with diabetes was relatively small. In addition, we were
not able to identify subjects with undiagnosed diabetes
or IGT in the baseline according to present-day diagnos-
tic criteria. Historically, there were multiple protocols
for the OGTT and only minor emphasis was on the 2-h
glucose value used today [28]. Therefore, some subjects
with diabetes might have been in the IGT group. One
could also argue that the cutoff used to classify abnor-
mal OGTT result based on the 1-h glucose was too low
as the IGT group was relatively large. However, 1-h glu-
cose cutoff as low as 8.61 mmol/l (155 mg/dl) has been
shown to be associated with elevated hsCRP levels, in-
creased carotid intima media thickness, impaired insulin
sensitivity, future diabetes and cutoff 8.94 mmol/l
(161 mg/dl) has been shown to be associated with car-
diovascular deaths [29–31]. We were also unable to
identify subjects who developed IGT or diabetes during
the follow-up, which is likely to somewhat dilute the
hazard ratios observed. Finally, the generalizability of
our results to contemporary patient populations may be
limited because the prevalence of type II diabetes has
been increasing during the last decades in contrast to
the relatively large proportion of type I diabetes patients
in our cohort.
Conclusions
The risk of SCD among diabetes patients was high in
middle-aged general population, even in the absence of
established cardiac disease. However, these patients were
also at increased risk for non-sudden cardiac death and
the proportion of cardiac deaths being sudden among
diabetes patients was not elevated. IGT was associated
with increased risk of SCD as well, but its independent
contribution as a risk factor warrants further research as
adjustment for other confounders attenuated this effect.
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